Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center phase II randomized study of CustOmized Neoadjuvant ThErapy vs Standard chemoTherapy in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA (N2) disease (CONTEST trial) Studio multicentrico randomizzato di fase II con terapia neoadiuvante personalizzata verso chemioterapia standard nel tumore polmonare non a piccole cellule con malattia operabile in stadio IIIA (N2) (Studio CONTEST)

X
Trial Profile

A multi-center phase II randomized study of CustOmized Neoadjuvant ThErapy vs Standard chemoTherapy in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA (N2) disease (CONTEST trial) Studio multicentrico randomizzato di fase II con terapia neoadiuvante personalizzata verso chemioterapia standard nel tumore polmonare non a piccole cellule con malattia operabile in stadio IIIA (N2) (Studio CONTEST)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin; Docetaxel; Gefitinib; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONTEST
  • Most Recent Events

    • 25 Nov 2014 Biomarkers information updated
    • 20 Jun 2013 Trial protocol presented at ASCO 2013.
    • 05 Feb 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top